EGFR inhibitors such as Erbitux and Gilotrif show potential in laboratory and mouse studies in treating melanoma with a ...

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events (irAEs) that occur when the ...

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

Innovent Biologics presents data from phase 1 PoC study of IBI363 to treat advanced NSCLC at 2025 ASCO: San Francisco Friday, June 6, 2025, 18:00 Hrs [IST] Innovent Biologics, Inc ...

The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more ...

Adjuvant T-DM1 significantly improves long-term invasive disease–free and overall survival versus trastuzumab in residual ...

Day One Biopharmaceuticals' Q1'25 sales grew modestly, but Q2 2025 earnings could spark movement. Read why I currently rate ...

Two new studies on NEFECON® demonstrate its treatment benefit in the 'Treat Early' strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: 'Treat the ...